Headache News and Research

Latest Headache News and Research

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Migraine affects an estimated 30 million people in the U.S, with the one year prevalence of migraine estimated at 12% of the general population, including 18% of all women and 6% of all men.

12 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Viewpoints: Obama budget doesn't address 'heart of our debt crisis;' Attention deficit crisis; Insurer sings a different song when consumer owes it money

The U.S. has huge budget challenges. And for the first time in years, we will have three budget proposals to carefully consider -- instead of speeches and talking points.

11 Apr 2013

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.

9 Apr 2013

Migraine sufferers should undergo more formal experiments, says study

Women often point to stress, hormones, alcohol, or even the weather as possible triggers for their migraines. But a new study from Wake Forest Baptist Medical Center found that it is nearly impossible for patients to determine the true cause of their migraine episodes without undergoing formal experiments.

8 Apr 2013

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.

8 Apr 2013

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

Clinical trial signals new era in treatment of neurodegererative disorders

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis - blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease - may be a first step towards a new era in the treatment of such disorders.

4 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

GE Healthcare today announced that it has submitted an application to amend its European Marketing Authorisation that will allow the company to manufacture Optison 0.19 mg/ml dispersion for injection within its own facility.

30 Mar 2013

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Pfizer Inc. announced today that the Japanese Ministry of Health, Labor and Welfare has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies.

25 Mar 2013

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

The U.S. Food and Drug Administration announced today that it has approved Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin.

25 Mar 2013

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.

24 Mar 2013

Roundup: Medicaid causes budget headache in Wash. state; Minn. plan to cut health services a surprise; Midwife access issues in N.C.

A selection of health policy stories from Washington state, Minnesota, North Carolina, Tennessee, Georgia, Arizona, California and Colorado.

22 Mar 2013

Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Fibromyalgia is a common disorder that is diagnosed in people who have pain in many areas of their body together with important symptoms such as...

22 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Dotarem gets FDA approval for use in patients undergoing CNS MRI

The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging of the brain, spine and associated tissues of patients ages 2 years and older.

21 Mar 2013

Migraine severity may be predicted by blood levels of fat cell hormone

In a small, preliminary study of regular migraine sufferers, scientists have found that measuring a fat-derived protein called adiponectin (ADP) before and after migraine treatment can accurately reveal which headache victims felt pain relief.

18 Mar 2013

Headache News and Research

Latest Headache News and Research

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Viewpoints: Obama budget doesn't address 'heart of our debt crisis;' Attention deficit crisis; Insurer sings a different song when consumer owes it money

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Migraine sufferers should undergo more formal experiments, says study

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

Clinical trial signals new era in treatment of neurodegererative disorders

Revance Therapeutics raises $33M in Series E financing

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

Roundup: Medicaid causes budget headache in Wash. state; Minn. plan to cut health services a surprise; Midwife access issues in N.C.

Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Dotarem gets FDA approval for use in patients undergoing CNS MRI

Migraine severity may be predicted by blood levels of fat cell hormone

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in